18

First Response: NSCLC Highlights From Chicago

  • Upload
    orinda

  • View
    49

  • Download
    0

Tags:

Embed Size (px)

DESCRIPTION

First Response: NSCLC Highlights From Chicago. RTOG 0617 Overall Survival Results. ALK Rearrangement Positive Advanced NSCLC. MPDL3280A Phase Ia: Response by PD-L1 IHC Status. GALAXY-1 Overall Survival: Adenocarcinoma. LUME Lung 1: Overall Survival Adenocarcinoma. - PowerPoint PPT Presentation

Citation preview

Page 1: First Response: NSCLC Highlights From Chicago
Page 2: First Response: NSCLC Highlights From Chicago
Page 3: First Response: NSCLC Highlights From Chicago
Page 4: First Response: NSCLC Highlights From Chicago
Page 5: First Response: NSCLC Highlights From Chicago
Page 6: First Response: NSCLC Highlights From Chicago
Page 7: First Response: NSCLC Highlights From Chicago
Page 8: First Response: NSCLC Highlights From Chicago
Page 9: First Response: NSCLC Highlights From Chicago
Page 10: First Response: NSCLC Highlights From Chicago
Page 11: First Response: NSCLC Highlights From Chicago
Page 12: First Response: NSCLC Highlights From Chicago
Page 13: First Response: NSCLC Highlights From Chicago
Page 14: First Response: NSCLC Highlights From Chicago
Page 15: First Response: NSCLC Highlights From Chicago
Page 16: First Response: NSCLC Highlights From Chicago
Page 17: First Response: NSCLC Highlights From Chicago
Page 18: First Response: NSCLC Highlights From Chicago

OVERVIEW AND HIGHLIGHTS: OVERVIEW AND EVALUATION HIGHLIGHTS · Overview and Highlights | P a g e 6 analysis. The Chicago neighborhood estimates are based on citywide, random sample

OVERVIEW AND HIGHLIGHTS: OVERVIEW AND EVALUATION HIGHLIGHTS · Overview and Highlights | P a g e 6 analysis. The Chicago neighborhood estimates are based on citywide, random sample

Documents
Multimodality Treatment Of Stage Iii Nsclc

Multimodality Treatment Of Stage Iii Nsclc

Health & Medicine
grad do highlights - University of Chicago · Roosevelt University University of Illinois at Chicago

grad do highlights - University of Chicago · Roosevelt University University of Illinois at Chicago

Documents
Chemo rt in nsclc 2011- jk

Chemo rt in nsclc 2011- jk

Business
Immunotherapy in NSCLC

Immunotherapy in NSCLC

Documents
Scientific Highlights of the HETE-2 Mission D. Q. Lamb (U. Chicago)

Scientific Highlights of the HETE-2 Mission D. Q. Lamb (U. Chicago)

Documents
From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia

From Inquiry to Investigation to Insight: Clinical Clarity in … · 2019. 12. 6. · EGFR in NSCLC •10% of NSCLC cases in North America •30%–50% of NSCLC cases in East Asia

Documents
Current standard of care of NSCLC · First TKI versus chemotherapy in EGFR mutated NSCLC. Mok, NEJM 2009. Rosell, Lancet Oncol 2012. First-line TKI therapy in EGFR-mutated NSCLC:

Current standard of care of NSCLC · First TKI versus chemotherapy in EGFR mutated NSCLC. Mok, NEJM 2009. Rosell, Lancet Oncol 2012. First-line TKI therapy in EGFR-mutated NSCLC:

Documents
LungNet: Shallow CNN models for NSCLC

LungNet: Shallow CNN models for NSCLC

Documents
Emerging Targets for Squamous Cell NSCLC

Emerging Targets for Squamous Cell NSCLC

Documents
Year in Review: Therapeutic Advances in Treating …...– ASCO Chicago 2017 – ESMO Madrid 2017 – WCLC Japan 2017 Outline 3 Molecular Classification of NSCLC: 2017 Rosell and Karachaliou

Year in Review: Therapeutic Advances in Treating …...– ASCO Chicago 2017 – ESMO Madrid 2017 – WCLC Japan 2017 Outline 3 Molecular Classification of NSCLC: 2017 Rosell and Karachaliou

Documents
Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%

Biomarker testing in non- small cell lung cancer (NSCLC) · NSCLC is both histologically and genetically diverse. 3. Prevalence of genetic alterations in NSCLC. 4. 40%. 25%. 10%

Documents
nonsquamous NSCLC

nonsquamous NSCLC

Health & Medicine
Mlm nsclc prevencion_oportuno_2016_b

Mlm nsclc prevencion_oportuno_2016_b

Health & Medicine
CHICAGO CHAPTER ICRI · Crack Repair Announcment ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter September Dinner 11 Meeting Highlights ... On December

CHICAGO CHAPTER ICRI · Crack Repair Announcment ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter September Dinner 11 Meeting Highlights ... On December

Documents
CHICAGO CHAPTER ICRI · 2020. 2. 9. · NOVEMBER 2019 ICRI/SEAOI CHICAGO CHAPTER SEMINAR HIGHLIGHTS Topic: Assessment and Repair of Concrete Structures The ICRI Chicago Chapter in

CHICAGO CHAPTER ICRI · 2020. 2. 9. · NOVEMBER 2019 ICRI/SEAOI CHICAGO CHAPTER SEMINAR HIGHLIGHTS Topic: Assessment and Repair of Concrete Structures The ICRI Chicago Chapter in

Documents
NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed

NSCLC - Stage IV STAGE IVNSCLC. NSCLC - Stage IV NSCLC Main Drugs Stage IV NAVELBINE:The pivotal drug GEMZAR:Main competitor TAXOL:Still often prescribed

Documents
PANERA BREAD (Corporate|Chicago MSA) 5500 West Touhy ... Bread - Skokie, IL - OM.pdfINVESTMENT HIGHLIGHTS: INVESTMENT HIGHLIGHTS • Located within the Chicago MSA • New construction

PANERA BREAD (Corporate|Chicago MSA) 5500 West Touhy ... Bread - Skokie, IL - OM.pdfINVESTMENT HIGHLIGHTS: INVESTMENT HIGHLIGHTS • Located within the Chicago MSA • New construction

Documents
HIGHLIGHTS OF PRESCRIBING INFORMATION When … · Non-Small Cell Lung Cancer (NSCLC) •in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment

HIGHLIGHTS OF PRESCRIBING INFORMATION When … · Non-Small Cell Lung Cancer (NSCLC) •in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment

Documents
HIGHLIGHTS OF PRESCRIBING INFORMATION …...• Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based

HIGHLIGHTS OF PRESCRIBING INFORMATION …...• Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based

Documents
CHICAGO CHAPTER ICRI · 2017. 2. 20. · ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter April Dinner 11 Meeting Highlights 5th Annual Chicago Chapter

CHICAGO CHAPTER ICRI · 2017. 2. 20. · ICRI Chicago Chapter November Dinner 10 Meeting Announcement ICRI Chicago Chapter April Dinner 11 Meeting Highlights 5th Annual Chicago Chapter

Documents
The Evolving Treatment Landscape in NSCLC

The Evolving Treatment Landscape in NSCLC

Documents
ADJUVANT THERAPY IN OLDER ADULTS: NSCLC

ADJUVANT THERAPY IN OLDER ADULTS: NSCLC

Documents
Nsclc slide deck

Nsclc slide deck

Health & Medicine
Nsclc 2nd line

Nsclc 2nd line

Health & Medicine
1 ACR 2011 Medical Passport Highlights of ACR 2011 Chicago, IL November 2011

1 ACR 2011 Medical Passport Highlights of ACR 2011 Chicago, IL November 2011

Documents
Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

Immune checkpoint inhibitors in NSCLC - OncologyPRO€¦ · Dxnot approved fordurvalumabin any setting Dxnot approved foravellumabin US/EU: any setting NSQ NSCLC EU: NSQ NSCLC Approved

Documents
Concurrent ChemoRT in NSCLC

Concurrent ChemoRT in NSCLC

Documents
Second line therapy for nsclc

Second line therapy for nsclc

Health & Medicine
CCO Metastatic NSCLC Slides

CCO Metastatic NSCLC Slides

Documents